CP-CML is defined by the presence of the BCR::ABL1 fusion gene, while BP-CML is diagnosed when blasts in peripheral blood (PB) or bone marrow (BM) exceed ≥20%, or when myeloid sarcoma or lymphoblast infiltration is present. This evidence concerns the gene BCR and myeloid sarcoma.